- 12 oral surgery updates in 2026
- 5 ASC, MOB deals in California
- Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
- The Aspen Group’s 3-year growth recap: 40 moves
- Florida State University set to acquire Tallahassee hospital
- How Confusing Financial Journeys Undermine Revenue and Trust
- How Confusing Financial Journeys Undermine Revenue and Trust
- Misalignment, Not Malice: Rethinking Generational Conflict in Healthcare
- If AI ‘adds friction, it fails’: How Mayo Clinic scales technology
- As maternity units close, AdventHealth restores OB care in rural Kansas
- Oklahoma officials warn of new opioid
- The new metrics of healthcare technology ROI: What matters to healthcare leaders
- Hoag to launch transplant center in 2027
- MercyOne hospital to transition labor and delivery services
- MercyOne hospital to transition labor and delivery services
- Southeast metros lead US population growth as national gains slow
- 8 Medicare Advantage numbers to know in 2026
- 17 Senate Dems push back on 2027 ACA proposal
- Providence hospital closes inpatient pediatric unit
- Michigan finalizes Medicaid mental health assessment policy changes
- 10 financial notes on USPI’s growth over the past 3 years
- 15 new orthopedic practice, center openings in Q1
- The oral surgery technological revolution
- From Anxiety to Action: How Ambulatory Leaders Are Rebuilding Margins in 2026
- Where GI training may fall short
- What it took to become the world’s first ASC to offer Stryker’s robotic knee tech
- Medtronic’s win in spinal cord stimulator lawsuit upheld
- How the Trump Administration Uses Migrant Kids To Find and Detain Family Members
- Heartland Dental’s 3-year growth recap: 30+ moves
- Cencora’s $10B+ physician acquisition spree: A breakdown
- Tennessee physician practice acquired
- The FTC is coming for healthcare consolidation: 10 things physicians need to know
- Adventist Health sees momentum from insourcing revenue cycle operations
- Oral GLP-1s, COVID preventatives: 3 more drugs in the pipeline, Optum says payers should watch
- Unlicensed dentistry cases, DSO deals, legislation & more: 10 dentistry updates in Virginia
- Missouri system debuts mobile behavioral health unit
- Yale researchers study GLP-1’s potential for SUD
- Texas dental school receives $6.5M to expand pediatric dental, medical programs
- North Carolina autism provider to expand therapy access
- $3M Verdict Links Social Media to Anxiety and Depression
- West Virginia hospital to end OB delivery services
- 6 DSOs making headlines
- California hospital’s finances improve, cash position remains ‘dire’
- 1 in 5 metro markets face inpatient monopoly: 7 notes
- Minnesota system faces uncertainty amid Medicare delays
- Ohio county approves behavioral health crisis center plan
- The White House Delays CDC Pick
- New COVID 'Cicada' Variant Is Spreading — What Experts Want You To Know
- Op-ed: Empathy meets efficiency—how the responsible use of AI can transform Medicare
- Family Caregivers Provide $1 Trillion In Annual Labor, AARP Says
- ‘Health Doesn’t Need to Be Ludacris’: Bayer signs rapper-actor to multivitamin campaign
- Rocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA
- Healthy Lab Results May Mask Future Risks for Kids with Obesity
- At-Home Chemotherapy Is Safe, Feasible, Pilot Study Indicates
- What You Do While Sitting Could Predict Dementia Risk
- New Cholesterol Guidelines: What Patients and Caregivers Need to Know
- Want A Bootlicking Yes Man? Ask An AI Chatbot For Advice, Study Warns
- Specially Coated Implants Better For Breast Cancer Patients, Study Finds
- Trump Team Claims Successes Against ACA Fraud While Pushing for More Controls
- Give and Take: Federal Rural Health Funding Could Trigger Service Cuts
- Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo
- Where are you with EUDAMED?
- Where are you with EUDAMED?
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Why private practice dentistry needs a better model
- CareQuest Innovation Partners, Kno2 collab on medical-dental data integration
- Nonprofit highlights rural opioid care strategies
- Vitana Pediatric & Orthodontic Partners adds Florida practice
- What the Health? From KFF Health News: A Headless CDC
- 20 behavioral health leaders challenge industry assumptions
- Recordati confirms it's weighing CVC Capital buyout offer of $12.6B
- 3 California behavioral health centers to close amid funding shifts
- Indiana bars autism therapy provider from Medicaid billing: Wall Street Journal
- UnitedHealth shareholder sues over proposal to include details on integration in annual proxy
- SCAN taps biopharma, CMS vet Aman Bhandari as its first chief AI officer
- Infosys to acquire Optimum Healthcare IT in $465M deal
- DOJ alleges NewYork-Presbyterian forces payers into anticompetitive 'all-or-nothing' contracts
- FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
- Bees and Hummingbirds May Be Consuming Small Amounts of Alcohol
- Two States Sue Cord Blood Company Over Misleading Claims
- New WHO Guidance Aims To Speed Tuberculosis Testing
- As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
- Trump admin delays nomination for new CDC director past deadline
- Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
- Egg-based drugmaker Neion Bio emerges from stealth to cook up multi-product biosimilar collab
- Genentech walks the walk in lupus as sponsor of annual awareness and fundraising event
- Study Reveals How Many Americans Consider Using a Gun
- Massive Study Finds Stress and Grief Don’t Cause Cancer
- Ultra-Processed Foods Harm Fertility In Both Men And Women, Studies Reveal
- Small Daily Habits Can Add Up To Better Heart Health
- Ritalin Might Protect ADHD Kids' Long-Term Mental Health, Study Finds
- Can You Drink Enough Fluids To Prevent Kidney Stones? Maybe Not, New Study Says
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- Remarks at the Financial Stability Oversight Council Meeting
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- New therapy animal program aims to support 100K patients, providers
- Pulse check on Lilly's GLP-1 fortunes
- Gen Z nurses prioritize schedule flexibility, need more manager interactions to avoid turnover
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
- Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep
- ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode
- Alcohol Prep Pads Recalled Over Bacteria Risk, Cardinal Health Says
- Fewer patients traveled for abortions in 2025 as telehealth care increased, report finds
Beyond RFK, Jr., there are a number of individuals in the running to take various health care posts in the upcoming Trump Administration:
https://rollcall.com/2024/11/07/a-look-at-those-who-could-be-on-trumps-health-team-short-list/
A look at those who could be on Trump’s health team short list
RFK Jr., Jindal among those thought to be contenders for key Trump health positions
By Ariel Cohen - November 7, 2024President-elect Donald Trump has pledged to involve anti-vaccine activist and conspiracy theorist Robert F. Kennedy Jr. in his next administration in some capacity, but whoever else he picks to run the major health agencies will have a major impact on the GOP health agenda of the next four years.
Top posts require Senate confirmation, meaning Trump will need Senate buy-in too. Positions include Health and Human Services secretary, which requires Senate confirmation; Centers for Disease Control and Prevention director, which will require Senate confirmation beginning in January 2025; Food and Drug Administration commissioner and National Institutes of Health director, which also require Senate confirmation.
Republican health priorities will likely include increased health care transparency and lowering drug costs, as well as limiting health care access for LGBTQ individuals and, potentially, further limiting access to abortion. This might look like rolling back Title X regulations, which are federal dollars for family planning, or the Mexico City policy, which blocks federal funding for nongovernmental organizations that provide abortion counseling or services.
It could also look like rollbacks of rules regarding nondiscrimination in health care, drug price negotiation interference or nursing home staffing mandates.
Here are some of the names being mentioned for future Trump health policy roles:
Robert F. Kennedy Jr.
Trump reiterated his pledge to involve RFK Jr. in his administration during his victory speech on Tuesday, but it’s unlikely he’ll be nominated to lead a major agency.“He’s going to help make America healthy again. He’s a great guy and he really means it. He wants to do some things, and we’re going to let him go to it,” Trump told supporters at the West Palm Beach Convention Center during his victory speech Tuesday night.
In an MSNBC interview on Wednesday morning, Kennedy said he would clear out entire departments of the FDA, including the nutrition department, which was recently revamped as part of the agency’s effort to create a Human Foods Program.
Many experts say they imagine Kennedy will serve more as an informal adviser to Trump, because it could be difficult to get a majority of senators, even in a GOP-led chamber, to confirm him.
“I see someone like that a little more in kind of the Elon Musk type of role … somebody who is whispering in the ear of the administration,” said K&L Gates government affairs adviser and former RNC delegate Amy Carnevale.
Joseph A. Ladapo
Florida Surgeon General Joseph Ladapo is under consideration to lead HHS, ABC News first reported.Like Kennedy, Ladapo is a vaccine skeptic.
Under his leadership, Florida skirted CDC pandemic guidelines regarding masks and social distancing, as well as vaccine requirements for children. In October 2022, he recommended that men between ages 18 and 39 avoid the COVID-19 mRNA vaccines because of a slightly increased risk for cardiac-related deaths. The study he referenced was widely criticized, and the FDA and CDC sent him a letter asking him to stop spreading disinformation.
Lapado was first appointed by Republican Gov. Ron DeSantis in 2021.
After Trump’s win, Ladapo tweeted on Wednesday that the “future of health freedom in America looked brighter.”
“Just as in Florida, it’s time to say ‘No’ to trampling on people’s rights, to gaslighting citizens about experimental vaccines that harm instead of help & to muzzling doctors who dissent with orthodoxy. Light triumphs over darkness,” he said.
Roger Severino
Roger Severino, the former director of the HHS Office of Civil Rights under Trump and current vice president of domestic policy at the Heritage Foundation, wrote the HHS portion of Project 2025.Severino is one of the most vocal abortion opponents in the GOP. He has repeatedly said that the government should not treat abortion as health care and calls for reversing approval of medication abortion, codifying the Hyde amendment and removing the morning-after pill from the contraceptive mandate.
In Project 2025 he also encourages the NIH to stop promoting “junk gender science” and redefine the definition of sex so it does not include gender identity, among other things.
Brian Blase
Brian Blase, a former Trump special assistant to the president for economic policy at the White House’s National Economic Council and currently the president of Paragon Health Institute, could come back around for a second administration.In his most recent email blast, Blase called Trump’s victory “an opportunity to build on the health care successes of his first term” — pointing mainly to policies that expanded the availability of short-term health plans, association health plans and price transparency.
During the Biden administration, Blase has been analyzing and promoting the expansion of health savings account plans. He has proposed providing lower-income exchange enrollees the option to receive a portion of their subsidy as a HSA deposit rather than a subsidy to the insurer.
He also argued against the Biden administration’s expansion of Medicaid during the COVID-19 public health emergency, and called for limiting the program’s scope to just the lowest-income and most vulnerable individuals.
Paul Mango
Mango, another former Trump administration official and an adviser at the Paragon Institute, served as HHS deputy chief of staff from 2019 through 2021 and served as HHS Secretary Alex Azar’s formal liaison to Operation Warp Speed. From 2018 to 2019, Mango served as chief of staff for the Centers for Medicare and Medicaid Services. His institutional knowledge of the department could be seen as an asset to an incoming Trump administration.Eric Hargan
Another Trump administration alumni, Eric Hargan served as deputy HHS secretary under Trump and also as acting secretary. He also served on the board of Operation Warp Speed. Hargan oversaw the setup and launch of the pandemic-era Provider Relief Fund.Hargan was also acting HHS deputy secretary under then-President George W. Bush.
These days he’s the founder and CEO of the Hargan Group, where he focuses on health care, government relations and public affairs.
Joe Grogan [not the podcaster!]
Joe Grogan served as an assistant to Trump and director of his Domestic Policy Council. He also was a member of the White House Coronavirus Task Force in the early days of the pandemic. But Grogan didn’t stay in the administration the entirety of the first term and resigned in May 2020 to join Verde Technologies.During his time in the White House, Grogan worked closely on efforts to lower drug costs, ban surprise medical bills and expand COVID-19 testing. He’s been a vocal opponent of the Biden administration’s policies to have Medicare negotiate drug costs, saying it would lead to less pharmaceutical innovation, and has repeatedly called for FDA reform to speed up the drug review and approval process.
These days Grogan is also at Paragon Health Institute where he serves as chairman of the board.
Bobby Jindal
The former Louisiana governor is now chair of the Center for a Healthy America, a wing of the America First Policy Institute, a conservative think tank advising Trump. Jindal’s focus on health policy isn’t new: he served as HHS assistant secretary under George W. Bush. Over the last few years he’s called for changes to the health care exchanges, increased price transparency measures and advocated against single-payer health care.
Robert F. Kennedy, Jr. is not the only Trump nominee catching flack. The smart, prescient Dr. Jay Bhattacharya is also catching slings and arrows from envious nonentities:
Pandemic Hawks Circle Dr. Jay: Pundits Launch Attacks on Bhattacharya Ahead of his Confirmation HearingsBy Jonathan Turley - December 29, 2024
For those who opposed the censorship and cancel campaigns during the pandemic, Dr. Jay Bhattacharya became an iconic figure of resistance. Unfortunately, the same can be said of the anti-free speech movement and pandemic hawks. Bhattacharya, who co-authored the Great Barrington Declaration and was a vocal critic of COVID-19 policies, has been nominated as the next head of the National Institutes of Health. As I wrote this weekend in my column, the nomination was heralded by many as a turning point for the NIH. It is also a rallying cry for those who supported the earlier measures, as shown by a hit piece in Scientific American, accusing him of being a danger to the very lives of American citizens.
Bhattacharya was censored, blacklisted, and vilified for the last four years due to his opposing views on health policy, including opposing wholesale shutdowns of schools and businesses. He was recently honored with the prestigious “Intellectual Freedom” award from the American Academy of Sciences and Letters.
Before the pandemic, Bhattacharya was one of the most respected scientists in the world and served as the director of Stanford’s Center for Demography and Economics of Health and Aging.
That all changed when he dared to question the science behind pandemic policies, including suggesting that natural immunity would be as good if not better protection for young healthy individuals.
It did not matter that positions once denounced as “conspiracy theories” have been recognized or embraced by many.
Some argued that there was no need to shut down schools, which has led to a crisis in mental illness among the young and the loss of critical years of education. Other nations heeded such advice with more limited shutdowns (including keeping schools open) and did not experience our losses.
Others argued that the virus’s origin was likely the Chinese research lab in Wuhan. That position was denounced by the Washington Post as a “debunked” coronavirus “conspiracy theory.” The New York Times Science and Health reporter Apoorva Mandavilli called any mention of the lab theory “racist.”
Federal agencies now support the lab theory as the most likely based on the scientific evidence.
Likewise, many questioned the efficacy of those blue surgical masks and supported natural immunity to the virus — both positions were later recognized by the government.
Others questioned the six-foot rule, which shut down many businesses, as unsupported by science. In congressional testimony, Dr. Anthony Fauci recently admitted that the rule “sort of just appeared” and “wasn’t based on data.” Yet not only did it result in heavily enforced rules (and meltdowns) in public areas, but the media further ostracized dissenting critics.
Again, Fauci and other scientists did little to stand up for these scientists or call for free speech to be protected. As I discuss in my new book, “The Indispensable Right,” the result is that we never really had a national debate on many of these issues and the result of massive social and economic costs.
Now, those who supported these policies are gathering to oppose Bhattacharya.
It is hardly surprising that one of the first hit pieces came from Scientific American. The magazine not only helped lead the mob response to the pandemic but has also been criticized for abandoning neutrality in recent elections.
Only a few weeks ago, editor-in-chief Laura Helmuth posted a raving, profanity-laden meltdown on social media in which she effectively called over 77.3 million Americans who voted for President-elect Donald Trump both “fascists” and bigots.
Now the magazine has published an article by Dr. Steven Albert, a professor and the Hallen Chair of Community Health and Social Justice at the University of Pittsburgh’s School of Public Health.
Two specific attacks stand out in the piece.
The “Personal Pique” of Censorship
First, Dr. Albert suggests that Dr. Bhattacharya was never actually censored. He insists that what Bhattacharya calls censorship was merely the fact that “social media venues … dropped his messaging.” It is curious wording and it is not quite clear what Dr. Albert is trying to say.
When Albert’s article appeared, various other outlets advanced the same claim. For example, MSNBC (which also was a leading outlet in the attacks on skeptics and dissenters during the pandemic) mocked the claim that Bhattacharya was censored.
“The problem is there’s basically zero evidence to support Bhattacharya and his supporters’ claims of censorship. It is true that some internet sites appeared to remove or limit access to the document. But, as with medical professionals not being sure how best to handle Covid, the same was true of social media companies, which struggled with how best to handle the spread of potentially dangerous information that could have resulted in harm to users.
Many companies chose, of their own free will and as they were allowed as private actors, to downplay certain information that they felt might do more harm than good. That is their own First Amendment-protected right as private entities in the United States.”
The article goes on to suggest that there is no proof of censorship without government direction or control.
As the ACLU has long maintained, censorship occurs in both private and governmental forums. The same figures insist that, if there is no violation of the First Amendment (which only applies to the government), there is no free speech violation. The First Amendment was never the exclusive definition of free speech. Free speech is viewed by many of us as a human right; the First Amendment only deals with one source for limiting it. Free speech can be undermined by private corporations as well as government agencies.
There is also ample evidence of government officials pushing social media companies to censor pandemic critics. MSNBC simply excuses the censorship by saying that these companies “struggled with how best to handle the spread of potentially dangerous information that could have resulted in harm to users.” In reality, the censorship itself cost the nation greatly. We never had the type of debate that we need on the efficacy of natural immunities, masks, or other precautions. We never explored the science supporting the six-foot rule. We suffered immense costs in education and the economy rather than allowing scientists on both sides to be heard equally on such forums.
Instead, Bhattacharya became a persona non grata in academia and was subjected to cancel campaigns. In the Los Angeles Times, columnist Michael Hiltzik decried how “we’re living in an upside-down world” because Stanford allowed these scientists to speak at a scientific forum. He was outraged that, while “Bhattacharya’s name doesn’t appear in the event announcement,” he was an event organizer. Hiltzik also wrote a column titled “The COVID lab leak claim isn’t just an attack on science, but a threat to public health.”
Critics of Bhattacharya have also cited the fact that he retained his position, unlike some who were dropped by their institutions or associations. Survival is hardly the test of whether someone was censored or canceled. Bhattacharya holds a position with academic protections, as do some of us fortunate to have tenure in this age of rage. The fact that he persisted and the American people rejected the establishment in this election is not proof that he was not targeted or blocked from academic settings or social media sites.
Dr. Albert dismisses the censorship debate as a “personal pique” and “a distraction” that “should not obscure the central focus of U.S. public health policy during the pandemic.” Obviously, for many of us who value free speech and a diversity of viewpoints, it is a bit more than a “personal pique.”
The “Vanity” of Personal Autonomy
The second point that stood out in the Scientific American article was the warning that Bhattacharya is too focused on individual rights and personal autonomy to be the head of NIH. Dr. Albert declares:
“Pitting personal autonomy against the application of science to policy is fine for vanity webcasts and think tanks, but inappropriate for NIH leadership. If he would rather focus on promoting personal autonomy in pandemic policy, perhaps he is being nominated to the wrong agency.”
It is a chilling observation from a leading public health figure. NIH leadership suggests policies impacting a nation and must balance the costs and benefits of any given course. The NIH states that it is focused not just on “scientific integrity” but “public accountability and social responsibility in the conduct of science.” Isn’t individual rights part of that responsibility?
I would hope that the head of NIH (indeed every NIH official) would place individual rights and personal autonomy as one of the most prominent considerations in setting policies.policy-making Indeed, the NIH routinely discusses and publishes papers on the importance of personal autonomy when discussing subjects like abortion.
These two points are linked on some level. The nation was divided on many COVID policies, and doubts only grew with the censorship and intolerance that was evident during the pandemic. The NIH contributed to that mistrust with its heavy-handed tactics and viewpoint intolerance. One of the victims of that period will now head the NIH. That experience could be invaluable as Dr. Bhattacharya steers his agency toward a more transparent and tolerant path.
Jonathan Turley is the Shapiro professor of public interest law at George Washington University.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.

















